Covid 19 Research using Clinical Trials (Home Page)
Report for D009181: Mycoses NIH
(Synonyms: Mycoses)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug551 | COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection Wiki | 0.50 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055732 | Pulmonary Aspergillosis NIH | 0.71 |
| D001229 | Aspergillosis, Allergic Bronchopulmonary NIH | 0.71 |
| D001228 | Aspergillosis NIH | 0.50 |
| D003550 | Cystic Fibrosis NIH | 0.35 |
| D005355 | Fibrosis NIH | 0.27 |
| D003141 | Communicable Diseases NIH | 0.06 |
| D007239 | Infection NIH | 0.04 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
NCT04368221 Covid-19 MeSH:Mycoses
Primary Outcomes
Description: Prevalence of opportunistic fungal co-infections.
Measure: Opportunistic fungal co-infections. Time: at 12 monthsSecondary Outcomes
Description: Determination of the median time between entry in ICU and beginning of ARDS and (i) colonization and (ii) probable/proven infection with Aspergillus, Pneumocystis jirovecii and mucormycetes
Measure: Median time Time: at 12 monthsDescription: Evaluation of the time between diagnosis and targeted treatment
Measure: Time between diagnosis and targeted treatment Time: at ICU discharge, up to 1 monthDescription: Number of proposals for evaluation of preventive strategies if necessary, because of high incidence, in terms of chemoprophylaxis and/or environmental measures
Measure: Preventive strategies Time: At 12 months2 Immune Profiles in CF Fungal Infection
This study is investigating the role of allergic (Th2) inflammation in patients with Cystic Fibrosis (CF) and history of fungal infection and/or Allergic Bronchopulmonary Aspergillosis. Little is known about fungal infection in CF and conflicting results exist on whether this results in worse lung function over time. There is concern that persistent fungal infection can result in worse clinical outcome measures in patients with CF. Also, it is unclear how ABPA develops, but may be related to the amount of fungus a patient with CF is infected with. This study looks at inflammatory patterns and allergic responses to fungal elements to help identify biomarkers and signs of allergic disease in fungally infected patients with CF.
NCT04476758 Cystic Fibrosis Fungal Infection Allergic Bronchopulmonary Aspergillosis MeSH:Infection Communicable Diseases Mycoses Aspergillosis Pulmonary Aspergillosis Aspergillosis, Allergic Bronchopulmonary Cystic Fibrosis Fibrosis
Primary Outcomes
Description: Difference in sputum Th2 biomarkers (ECP, IL4, IL5, IL10, IL13, and eosinophil count) in patients with CF with fungal infection with expected elevation of sputum Th2 biomarkers in patients with CF and ABPA compared to those without fungal infection and without ABPA.
Measure: Difference in Th2 Sputum Markers Time: Average of 24 monthsSecondary Outcomes
Description: Serum Th2 biomarkers in patients with fungal infection and ABPA (Table 3). Serum Th1 biomarkers in patients with fungal infection and ABPA (Table 3). Serum sensitization markers to fungal allergens in patients with fungal infection and ABPA (Table 4). Baseline and historic lung function, historical comorbid diagnoses and BMI measurements in patients with fungal infection and ABPA. Environmental factors that are possibly related to fungal infection and ABPA in patients with CF. Immune profile: A profile of each group will be based upon their findings of each set of biomarkers: Th1, Th2, mold allergy panel, and systemic markers of inflammation. Based upon findings in each of these categories (elevated, depressed), we will be able to formulate a profile based upon the type of marker/inflammatory pathway.
Measure: Other markers of fungal inflammation and allergic reaction in patients with CF Time: Average of 24 monthsOther Outcomes
Description: Banking of both sputum and serum to potentially utilize microbiome and transcriptome techniques for further immunotyping and infection characterization.
Measure: Biobanking of specimens Time: Average of 24 months